tolterodine tartrate

DRUG6 trials

Sponsors

Pfizer, Merck Sharp & Dohme LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., University of California, San Francisco

Conditions

Overactive BladderUrge IncontinenceUrinary Bladder, OveractiveUrinary Incontinence, Urge

Phase 1

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

CompletedNCT00768521

Merck Sharp & Dohme LLCOveractive Bladder

Start: 2008-09-03End: 2009-01-19Updated: 2018-02-22

Pharmacokinetics and Relative Bioavailability Study

CompletedNCT01521767

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Urinary Bladder, Overactive

Start: 2011-10-31End: 2011-11-30Updated: 2021-01-27

Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

CompletedNCT00444925

PfizerOveractive Bladder

Start: 2007-04-30End: 2008-07-31Updated: 2015-03-24

Phase 4

Treatment of Incontinence Without Memory Problems

CompletedNCT02436889

University of California, San FranciscoUrge Incontinence, Urinary Incontinence, Urge

Start: 2016-02-29End: 2018-07-31Updated: 2019-04-16

Unknown Phase

Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).

CompletedNCT00795509

PfizerUrinary Bladder, Overactive

Start: 2007-08-31End: 2011-03-31Updated: 2012-07-09

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)

CompletedNCT01488578

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Overactive Bladder

Start: 2006-12-31End: 2011-03-31Updated: 2021-01-28

Related Papers

A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder.

2022-07-261 citations

Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder.

2011-03-2311 citations